Omnihealth Practice

New insights on the impact of tapering GCs or immunosuppressive therapy on damage accrual after achieving LLDAS and complete remission SLE

Systemic lupus erythematosus (SLE) is a lifelong disease with a median onset age of 15-44 years.1 As continued treatment with glucocorticoids (GCs) and immunosuppressive therapies can contribute to damage accrual, tapering of treatment is inevitable during the course of the disease.1 However, this c

RHEUMATOLOGY

02 Aug 2024

Validation of IMACS guidelines for enhanced cancer screening: A Hong Kong myositis cohort

Patients with adult-onset idiopathic inflammatory myopathy (IIM) are at increased risk of cancers.1 Recently, the International Myositis Assessment and Clinical Studies Group (IMACS) published recommendations on cancer risk stratification and screening for IIM patients.1 These include risk stratific

RHEUMATOLOGY

31 Jul 2024

The expanding role of musculoskeletal ultrasound in gout diagnosis and management in Hong Kong

MSUS has emerged as an invaluable diagnostic and prognostic tool in rheumatology, often complementing clinical evidence to bolster its role in managing patients with rheumatoid arthritis or juvenile idiopathic arthritis. During the 28^th Hong Kong Medical Forum, Dr. Ho, Tze-Kwan Carmen shared her insights on the implementation of MSUS and the interpretation of its results in gout management.

RHEUMATOLOGY

16 Jul 2024

Redefining the management of non-muscle-invasive bladder cancer in one swoop with en bloc resection over standard transurethral resection

Bladder cancer is one of the most prevalent cancers worldwide, with non-muscle-invasive bladder cancer (NMIBC) accounting for 75% of bladder cancer cases. While the standard piecemeal transurethral resection of bladder tumor (SR) has been the conventional surgical procedure for NMIBC, oncological control remains subpar, prompting the development of alternative techniques such as en bloc transurethral resection of bladder tumor (ERBT). To examine the impact of ERBT on the prognosis of NMIBC, Professor Teoh, Yuen-Chun Jeremy and his team conducted a local phase 3 randomized controlled trial, EB-StaR, that compared the 1-year recurrence rate of NMIBC with ERBT to SR. In an interview with Omnihealth Practice, Prof. Teoh discussed the implications of the results and the future of ERBT implementation.

ONCOLOGY UROLOGY

06 Aug 2024

Professor Teoh, Yuen-Chun Jeremy

Associate Professor,
Department of Surgery,
Faculty of Medicine,
The Chinese University of Hong Kong

Emphasizing HAE diagnosis and management in the Asia-Pacific region with SHARP guidance

Hereditary angioedema (HAE) is a rare, yet potentially life-threatening, inheritable disease characterized by episodic attacks of cutaneous and submucosal swelling.1,2 Unfortunately, the adoption and implementation of international guidelines established in Asia-Pacific (AP) populations remains limi

08 May 2024

Professor Li, Hei Philip

Clinical Assistant Professor,
Division Chief of Rheumatology & Clinical Immunology,
Department of Medicine,
The University of Hong Kong

EULAR 2024

June 12-15, 2024 | Vienna, Austria

Validation of IMACS guidelines for enhanced cancer screening: A Hong Kong myositis cohort

RHEUMATOLOGY

31 Jul 2024

New insights on the impact of tapering GCs or immunosuppressive therapy on damage accrual after achieving LLDAS and complete remission SLE

RHEUMATOLOGY

02 Aug 2024

AAN 2024

April 13-18, 2024 | Denver, United States

Novel MRI-based H-SeLECT risk score enhances the prediction of post-stroke epilepsy

Stroke is one of the most common causes of adult-onset seizures, which may occur early (≤7 days) or late (>7 days) after stroke.1 Post-stroke epilepsy (PSE) is defined as any unprovoked seizure after the acute phase (>7 days) of stroke.1 Approximately 4% of stroke patients experience PSE in the firs

NEUROLOGY

18 Jun 2024

Shotgun metagenomic analysis reveals gut dysbiosis in epilepsy patients

Despite the increasing availability of anti-seizure medication options, a substantial proportion of epilepsy patients, estimated at 30%-40%, continue to have drug-resistant disease.1 As such, treatment approaches beyond just pharmacotherapy have garnered increasing interest in recent years.1 Dietary

NEUROLOGY

14 Jun 2024

SC administration of vedolizumab receives FDA approval for Crohn’s disease maintenance

CD is an inflammatory bowel disease (IBD) with rising incidence and prevalence worldwide, characterized by abdominal pain, diarrhea, fatigue and weight loss. While corticosteroids (CS), immunomodulators and biologics are commonly used, achieving sustained remission remains varia

GASTROENTEROLOGY & HEPATOLOGY

08 Jul 2024

Local EHR-based ML model accurately predicts risk of severe hypoglycemia in older adults with diabetes

Severe hypoglycemia (SH), a dangerously low blood glucose level (<70mg/dL) that requires assistance from a third party, is a major concern for older adults with diabetes. Beyond the immediate medical emergency, SH is associated with a range of serious consequences, including prolonged hospitalizations, higher healthcare expenditures, increased risks of cardiovascular disease, falls, cognitive decline and elevated mortality. In response to this clinical challenge, researchers from CU Medicine developed a novel machine learning (ML) model capable of predicting the one-year risk of SH requiring hospitalization in older adults with diabetes. This predictive tool has the potential to enable targeted interventions and improve diabetes management outcomes in this high-risk population.

DIABETES & ENDOCRINOLOGY

02 Jul 2024

Global consensus reached on the definition and diagnostic criteria for GPP

GPP is a rare and severe auto-inflammatory disease characterized by recurrent, sudden, flares of widespread painful erythema and eruption of sterile pustules.^1,2 GPP flares may lead to life-threatening multi-organ complications if left untreated hence rapid and accurate diagnosis is needed.^2,3 However, clinical presentation of GPP is heterogeneous and symptoms may resemble other skin conditions, making accurate and timely diagnosis and treatment challenging.^1,3 As there is a lack of standardized international guidelines for GPP diagnosis, the International Psoriasis Council (IPC) established a Pustular Psoriasis Working Group to address these challenges and develop an international consensus definition and diagnostic criteria for GPP.^1,3

DERMATOLOGY

08 Jul 2024

Sequencing retreatment with anti-CD38 mAb in heavily pretreated RRMM patients

Patients with multiple myeloma (MM) are highly susceptible to developing relapsed and refractory (RR) disease towards lenalidomide and proteasome inhibitors (PIs) and require new active treatments at relapse. As such, novel treatment options like isatuximab, a monoclonal antibody (mAb) that targets

HEMATOLOGY

06 Mar 2024

Professor Yong, Kwee

University College London,
United Kingdom

Examining real-world effectiveness of fremanezumab in migraine prevention: Insights from the 3^rd interim analysis of PEARL

Migraine is a neurologic disorder characterized by recurrent attacks of pulsating headache that may be accompanied by an array of sensory symptoms or even cognitive dysfunction. Traditional treatments for migraine prevention are rarely disease-specific with unsatisfactory effectiveness and tolera

NEUROLOGY

01 Jan 2024

Every update. In your inbox.

Get access to our exclusive articles.

Overseeing local ocular health with a watchful gaze: Consensus on managing center-involving DME in Hong Kong

Diabetic macular edema is a prevalent cause of vision loss among individuals in the working-age population, characterized by the disruption of the blood-retinal barrier and the accumulation of fluid and serum macromolecules in the intercellular space. As the incidence of diabetes mellitus

OPHTHALMOLOGY

02 Jul 2024

Refining the management of hyperkalemia in the Asia-Pacific region: Consensus statements from a multidisciplinary expert panel

Hyperkalemia, defined as serum potassium >5.0mmol/L, is a potentially lethal condition as it hinders muscle function and myocardial excitability, which may contribute to arrhythmias and sudden cardiac deaths. Epidemiological data suggests the global prevalence of hyperkalemia is around 6.3%, but the

NEPHROLOGY

20 Jun 2024

Nephrology. 2024

Yap YHD, Ma CWR, Wong CKE, Tsui SHM, Yu YTE, Yu V, Szeto CC, Pang WF, Tse HF, Siu CDW, Tan CBK, Chen WCW, Li CL, Chen W, Chan TM. Consensus statement on the management of hyperkalaemia—An Asia-Pacific perspective. Nephrology. 2024;29(6):311-324.

Case sharing: Improving treatment outcome in MDD patients with timely brexpiprazole augmentation

Treatment-resistant depression (TRD) is defined as treatment failure following ≥2 trials of antidepressant therapy (ADT) at adequate doses, duration and adherence.1 Around 30% of patients with major depressive disorder (MDD) become resistant to conventional treatments.2 TRD is independently associa

PSYCHIATRY

09 May 2024

Dr. Lai, Chi-Lun

Specialist in Psychiatry

Case sharing: Brexpiprazole augmentation in MDD patients with anxiety symptoms provides the trifactor of clinical outcomes, patient compliance and functional recovery

Among patients suffering from major depressive disorder (MDD), more than half of them are encumbered with comorbid anxiety symptoms.1 They represent a more severe form of depression and are often associated with higher morbidity.2 Recovery is more difficult due to a reduced likelihood of response to

PSYCHIATRY

13 Mar 2024

Dr. Tso, Kwok-Chu

Specialist in Psychiatry

Exploring TYK2-targeted approaches: Deucravacitinib demonstrates notable efficacy and tolerability as a first-in-class treatment for psoriasis

DERMATOLOGY

02 Aug 2024

Dr. Linda Stein Gold

Director of Dermatology Clinical Research,
Henry Ford Health System,
Detroit, United States

Reshaping CLL care: Acalabrutinib-based regimens at the forefront of CLL management

HEMATOLOGY

09 May 2024

Dr. Jeff Sharman

Willamette Valley Cancer Institute and Research Center,
Eugene, United States

Infographics

OPHTHALMOLOGY NEPHROLOGY

Insight into CKD progression: Ophthalmalogical outcomes and eGFR in non-diabetic CKD

21 Jun 2024

CARDIOLOGY

CKD or No CKD: Knocking down CV risks with rosuvastatin

08 Jul 2024

NEUROLOGY

Longitudinal assessment of MCI and dementia in an essential tremor cohort

08 Jul 2024

HEMATOLOGY

From bridging to maintenance: A case of gilteritinib in RR FLT3 AML patients undergoing HSCT

09 May 2024

NEUROLOGY

Real-world effectiveness of fremanezumab in migraine prevention

08 Apr 2024

HEMATOLOGY CARDIOLOGY

Incidence of anemia with long-term low-dose aspirin

18 Mar 2024

Decoding the spectrum of tolerance in fish allergies

04 Jan 2024

DIABETES & ENDOCRINOLOGY CARDIOLOGY

Earlier and higher risk of CVD with a younger T2D diagnosis

04 Jan 2024

DIABETES & ENDOCRINOLOGY

U-shaped relationship between sleep duration and T2DM regardless of traditional lifestyle risk factors

17 Nov 2023

RESPIROLOGY

Brain Gliosis: A Potential Origin of Persistent Post-COVID-19 Depressive and Cognitive Symptoms

17 Nov 2023

DIABETES & ENDOCRINOLOGY NEUROLOGY

The nuanced link between prediabetes and dementia

23 Aug 2023

NEUROLOGY RHEUMATOLOGY

Connecting the dots between Parkinson’s disease and rheumatoid arthritis

12 Jul 2023

CARDIOLOGY PEDIATRICS

Cardio-oncology monitoring in pediatric populations - Delphi consensus recommendations from an Australian and New Zealand expert group

28 Apr 2023

RESPIROLOGY

Targeting TSLP for severe asthma - Tezepelumab updates from the 2023 American Academy of Allergy Asthma & Immunology Annual Meeting

06 Apr 2023

HEMATOLOGY PEDIATRICS

A new way out for alpha thalassemia major - Give them a chance at life with In-utero transfusions

15 Mar 2023

RESPIROLOGY

Beware of overlapping phenotypes in severe asthma: The eosinophilia and IgE double whammy

27 Feb 2023

NEPHROLOGY

Stay on the path of treatment - Take on a high-K with ease
ASN abstract highlight on sodium zirconium cyclosilicate and hyperkalemia

23 Feb 2023

RESPIROLOGY

Real-world effectiveness of benralizumab around the globe

06 Dec 2022

RESPIROLOGY

Remission is within reach - Target the underlying drivers of inflammation with benralizumab

19 Sep 2022

ONCOLOGY RESPIROLOGY

PACIFIC-6: Durvalumab after CRT showed similar safety profile as the PACIFIC regimen with encouraging efficacy data in frailer and older patients with stage 3, unresectable NSCLC